John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
News|Videos|February 20, 2026
María Teresa Bourlon, MD, MS, FASCO, previews practice-changing research at ASCO GU 2026
Author(s)María Teresa Bourlon, MD, MS, FASCO
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Bourlon outlines what to watch for in prostate, urothelial, kidney, and testicular cancer.
Advertisement
Advertisement
In this preview of research expected at the 2026 ASCO Genitourinary Cancers Symposium, medical oncologist María Teresa Bourlon, MD, MS, FASCO, outlined major clinical advances anticipated across prostate, urothelial, kidney, and testicular cancers. Speaking from her practice at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, she emphasized that the meeting will focus heavily on survival outcomes, biomarker-guided therapy, and emerging treatment mechanisms.
Related to this article
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Advertisement
Advertisement